TST Antibodies

Thiosulfate sulfurtransferase (TST)

Formation of iron-sulfur complexes, cyanide detoxification or modification of sulfur-containing enzymes. Other thiol compounds, besides cyanide, can behave as sulfur ion acceptors.

Also has weak mercaptopyruvate sulfurtransferase (MST) activity (By similarity). Together with MRPL18, functions as a mitochondrial import factor for the cytosolic 5S rRNA.

Gene Information

Human
Gene Name:	TST
Uniprot:	Q16762
Entrez:	7263

Family

Belongs to:
No superfamily

Alternative Names

EC 2.8.1; EC 2.8.1.1; MGC19578; RDSRhodanese; thiosulfate sulfurtransferase (rhodanese); thiosulfate sulfurtransferase

Molecular Weight

Mass (kDA):
33.429 kDA

Genomic Context

Human
Location:	22q12.3
Sequence:	22; NC_000022.11 (37010859..37020183, complement)

Subcellular Localizations

Mitochondrion matrix.

Diseases

• Tuberculosis
• Latent Tuberculosis
• Tuberculosis, Pulmonary
• Depressive Disorder
• Hiv Infections
• Active Tuberculosis
• Sleep Apnea Syndromes
• Apnea
• Infective Disorder
• Sleep Disorders
• Sleeplessness
• Immunologic Deficiency Syndromes

• Sleep Initiation And Maintenance Disorders
• Sleep Apnea, Obstructive
• Sturge-weber Syndrome
• Anxiety Disorders
• Arthritis
• Malnutrition
• Cross Infection

Pathways

• Swimming
• Immune Response
• Secretion
• Reflex
• Locomotion
• Hypersensitivity
• Pathogenesis
• Sensitization
• Transport
• Aging
• Neurogenesis
• Drug Resistance
• Cell Proliferation

• Excretion
• Circadian Rhythm
• Menopause
• Flight
• Neuroprotection
• Virulence
• Cytokine Production

PTMs

• Oxidation
• Phosphorylation
• Hydroxylation
• Demethylation

• Cleavage
• Acetylation
• Reduction
• Acylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/TST

Best Uses of the TST Marker by Boster Bio

This article covers the use of Boster Bio's anti-Cd40/Cd40 antibody, Picoband(tm) and the anti-Cytokeratin 19 KRT19 antibody. Each of these antibodies has specific uses. Here are the best uses for each. For more information, please read the complete article: Best uses of the TST marker

Picoband(tm), Boster Bio's anti CD40/Cd40 anti-CD40 antibody

Boster Bio's anti CD40 / CD40 antibody Picoband (tm) has been validated using multiple platforms and known positive and negative samples. The resulting product has high affinity and is highly specific. Boster also gives product credits to scientists who review the product. This program is open to all scientists worldwide. This article summarizes some of the product's strengths.

ABBV-323 binds with the antiparallel region on CD40. This non-polar molecule stabilizes the antiparallel heterodimer and prevents the monomers forming a functional dimer. Picoband(tm), an anti-CD40/Cd40 antibody, is compatible with other antibodies as well as those that target the same receptor.

CD40 is a member in the tumor necrosis receptor superfamily. It mediates tumor apoptosis, and regulates immune activation. Antibodies targeting CD40 have a direct cytotoxic effect upon tumor cells in murine models of T-cell-mediated immunity. By activating these antigen-presenting cells, agonist anti-CD40 antibodies have therapeutic potential.

CD40 is a 48-kD type I glycoprotein. It is a member of the TNFR family. It is expressed in B cells, macrophages, endothelial, and follicular dermritic cell types. It is important for T cell-B cell interactions. The 5C3 antibody promotes B cell proliferation in the presence of anti-IgM antibodies and inhibits the binding of CD40 to CD40L. The antibody is able to inhibit CD40 binding and CD40L binding, thus saving B cells.

The ABBV-323 Fab structure has been solved at a resolution of 1.74 A. It identifies a conformational Epitope that was previously unknown. Moreover, the crystal structure also illustrates that two loops and diverse charge of CD40 are required to bind to it. The CD40 antigen is similar to CRD1 or CRD2 proteins.

FAB516, the anti-CD40/Cd40 antibodies, has been characterized and analyzed. The antibody is a synthetic peptide and is intended to bind monomers CD40. Its structure is anti-parallel and has three cysteinerich domains. The Fab/CD40 fusion is achieved via hydrophobic, polar interactions. Furthermore, charge complementarity plays a significant role in the association between CD40L and CD40L.

KPL-404 is designed to bind human CD40. It has been tested on primary human B cells, including lymphoid cells. It binds well to CD40 from healthy donors. It also inhibits pathogenic B cell responses in autoimmune disorders. KPL404, a humanized anti CD40 antibody, was tested against the G28-5 monoclonal antibody to determine its efficacy.

KPL-404 inhibits the proliferation and differentiation of B cells. It also inhibits CD40L/CD40-mediated in vitro activation of B cell. Its agonistic activity may be useful in the treatment of autoimmune disorders. The potential therapeutic use of KPL-404 was also demonstrated in this study. Its agonistic qualities could prove useful in clinical trials or for guiding drug development.

Boster Bio's anti Cytokeratin 19KRT19 antibody Picoband,(tm),

This monoclonal antibody reacts against the rod domain human Cytokeratin-19. The antibody recognizes a 40kDa monoclonal antibody that reacts with the rod domain of human cytokeratin-19. It maps between amino acids 312 to 335. Cytokeratin 19 is not expressed in hepatocytes and therefore has a broad range of applications, including cancer detection and cytopathology. It can also be used to identify liver metastasis.

The antibody is produced by Boster Bio, an antibody manufacturer specializing in picogram sensitivity ELISA kits and IHC-optimized polyclonal antibodies. It has an impressive product line of over 12,000 antibodies, all of which are validated for IHC, WB, and Flow. Boster Bio's antibody are quantitatively validated against known amounts recombinant proteins as well as un-transfected cells.

Boster Bio's anti-Cytoperatin 19 KRT19 antibody is a Type I cytokeratin that reacts with Human, Mouse, and Rat cells. Because it is part of the Picoband(tm) catalog, it can be used for various applications. Flow Cytometry can be used to test anti-Cytokeratin 19 antibody, while IHC-P can use the antibody for immunohistochemical analysis.

This monoclonal anti-CK19 antibody can be used to detect tumor cells in peripheral blood, bone marrow, and breast tissue. Its dilution will be determined by the end-user lab and should be optimized accordingly. If tissues have been fixed in formalin, the antibody should be boiled in 10mM Citrate buffer pH 6.0 for 20 min and then cooled to RT. IHC can be performed using a prediluted version. Before detecting anti-CK19, you will need to remove epitopes.

Boster Bio's anti-ACE2 antibody

This mAb binds directly to the NTD in the viral protein. It prevents conformational change in the S protein. This prevents membrane fusion and viral entrance. Anti-ACE2-targeting mAbs bind to the RBD, forming a complex with Nb and inhibiting the binding of the RBD to ACE2. These mAbs can be more effective than those that target other parts of the virus.

The Boster Bio's anti-ACE2 antibodies have been tested in ELISA, immunofluorescence, and Western blot assays. These antibodies recognize the human ACE2 protein's amino acids 180-230. To reduce costs and prolong the immunogen, you can also use blocking peptides. The anti-ACE2 antibody is also used for immunofluorescence and immunohistochemistry.

Antibodies may be useful in the study of various diseases. Scientists believe that ACE alleles are associated with the severity of diseases. This gene is associated with the history of human migration. Lebanese people have an ACE allele frequency of 7*37% II. The ACE gene might also give information on the pharmacological significance this enzyme may have in different populations.

Vaccines for SARS-CoV-2 infection should stimulate the production of antibodies that block the interactions of ACE2-RBD and S-mediated membrane fusion. Studies of these interactions have identified that the S protein is an important antigenic target for SARS-CoV-2. These antibodies prevent SARS/CoV-2 from spreading by a variety means. They could be a powerful alternative for the anti-ACE2 antibodies currently used to treat the disease.